Mr. Richard R. DeLuca, Jr., is Executive Vice President, President Merck Animal Health of Merck & Co Inc. He is responsible for the Merck Animal Health organization. Prior to September 2011, Mr. DeLuca was Chief Financial Officer, Becton Dickinson Biosciences since 2010 and President, Wyeth?s Fort Dodge Animal Health division from 2007 to 2010. He served as Chief Operating Officer, Fort Dodge from 2006 to 2007 and Executive Vice President and Chief Financial Officer from 2002 to 2006.
Executive Vice President and Presidentident - Merck Animal Health
Age: 49 President Since 2011
The company has Return on Asset of 6.32 % which means that on every $100 spent on asset it made $6.32 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.21 % implying that it generated $11.21 on every 100 dollars invested.
The company has 20.57 B in debt with debt to equity (D/E) ratio of 0.37 which is OK given its current industry classification. Merck Co Inc has Current Ratio of 1.86 which is typical for the industry and considered as normal.
Entity SummaryMerck & Co., Inc. offer various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care solutions worldwide. Merck Co Inc [MRK] is traded on New York Stock Exchange in USA. It is located in Whitehouse Station, NJ and employs 82,000 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| MRK NYSE
Merck Co Inc
Currency: USD - US Dollar
Traded on New York Stock Exchange
Merck Co Inc has less than 16.16 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Merck price boundaries
Promote Merck and Richard DeLuca